Antibodies against the Notch ligand DLL4 have been tested clinically against tumor angiogenesis, but are unlikely to block Notch3 signaling, which appears to be activated by the ligand JAG1 in ovarian cancers where Notch3 signaling has not become ligand-independent [41, 62–64]. The gene discussed is NOTCH3; the disease is ovarian cancer.